Black Diamond Therapeutics (BDTX) Non Operating Income (2019 - 2026)

Black Diamond Therapeutics (BDTX) has reported Non Operating Income for 8 consecutive years, with $2.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non Operating Income fell 24.73% year-over-year to $2.2 million; the trailing twelve-month figure through Jun 2026 stood at $9.3 million (down 3.96% YoY), and the FY2025 full-year result was $9.8 million, up 8.13% from the prior year.
• Non Operating Income declined to $2.2 million in Q2 2026 per BDTX's latest filing, from $2.2 million in the prior quarter.
• Across five years, Non Operating Income topped out at $3.0 million in Q4 2022 and bottomed at $172000.0 in Q1 2022.
• Historically, Non Operating Income has averaged $1.7 million across 5 years, with a median of $2.1 million in 2024.
• The widest YoY moves for Non Operating Income: up 1319.72% in 2022, down 58.25% in 2022.
• Over 5 years, Non Operating Income stood at $3.0 million in 2022, then plunged by 52.15% to $1.4 million in 2023, then surged by 58.26% to $2.3 million in 2024, then advanced by 8.91% to $2.5 million in 2025, then dropped by 13.71% to $2.2 million in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered $2.2 million, $2.2 million, and $2.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.